DIRS.INFO The most relevant business & tech news

☆ Exclusive-Eisai Expects 1,500 Alzheimer's Patients in China Launch, Sees ‘Huge’ Growth
▼ + stars: | 2024-02-04 | by ( Feb. | At P.M. | ) www.usnews.com time to read: +5 min

“China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer’s disease for Eisai,” a company spokesperson said. “The potential growth for Leqembi in China is huge.”Eli Lilly, which is developing a similar treatment called donanemab, told Reuters it has filed for approval in China. The Indianapolis-based company is now testing its drug in a 1,500-person trial with volunteers in China, Taiwan, South Korea and the EU, a spokesperson said. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Once on treatment, suitable patients undergo a series of MRI scans to monitor for potentially fatal swelling and bleeding in the brain.

Persons: Julie Steenhuysen, Andrew Silver CHICAGO, ” Eli Lilly, Biogen, Liu Zhou, Eisai, ”, Hidemaru Yamaguchi, Soeren Mattke, Mattke, Andrew Silver, Caroline Humer, Bill Berkrot Organizations: Reuters, EU, Leqembi, Guangdong Medical University, ” Citi, Psychiatry, Siemens Healthineers, University of Southern, University of Southern California Brain Health Locations: SHANGHAI, China, ”, Leqembi, The Indianapolis, Taiwan, South Korea, Eisai, United States, Japan, Europe, U.S, University of Southern California, Chicago, Shanghai

☆ What do we know about China’s respiratory illness surge?
▼ + stars: | 2023-12-01 | by ( Andrew Silver | ) www.reuters.com time to read: +4 min

SHANGHAI, Dec 1 (Reuters) - A request by the World Health Organization for more information on a surge in respiratory illnesses and clusters of pneumonia in children in China has attracted global attention. The following is what we know about the surge in illness in the world's second most populous country so far, and why experts think there is no need to panic. The National Health Commission told a news conference on Nov. 13 that there was an increase in incidence of respiratory disease without providing further details. IS MYCOPLASMA PNEUMONIAE A BIG WORRY? One concern about the surge in respiratory illness is mycoplasma pneumoniae, which has also spiked in other countries.

Persons: Maria Van Kerkhove, Rajib Dasgupta, mycoplasma pneumoniae, it's, Cecille Brion, Van Kerkhove, We're, Andrew Silver, Miyoung Kim Organizations: World Health Organization, WHO, Program, National Health Commission, Reuters, Pacific, Jawaharlal Nehru University, Doctors, Raffles Medical Group Beijing, Thomson Locations: SHANGHAI, China, Taiwan, WHO China, COVID, South East Asia, New Delhi

The full benefit for these Indian manufacturers will not be immediate, said Peter DeYoung, CEO of Piramal Pharma Solutions. Nimgaonkar said Indian CDMOs need to do more to ensure their reputation on quality standards matches Western and Chinese ones. The Indian CDMOs told Reuters that their facilities are routinely inspected by the FDA. Aragen counts seven of the 10 biggest pharma companies as clients, he said, declining to name them. "New biotechs are deciding to put eggs in both the Indian and China baskets from the start," Subramanian said.

Persons: Trump, Tommy Erdei, Ashish Nimgaonkar, Nimgaonkar, Sai, Peter DeYoung, Helen Chen, CDMOs, Piramal, DeYoung, Ramesh Subramanian, Subramanian, Maggie Fick, Andrew Silver, Michele Gershberg, Catherine Evans Organizations: Jefferies, Glyscend Therapeutics, Reuters, Sciences, Piramal Pharma, Sai Life Sciences, Western pharma, Piramal Pharma Solutions, L.E.K, Consulting, pharma, U.S . Food, Drug Administration, FDA, Thomson Locations: China, India, SHANGHAI, HYDERABAD, U.S, Shanghai, United States, London, Hyderabad

☆ China's respiratory illness surge not as high as pre-pandemic- WHO official
▼ + stars: | 2023-11-27 | by ( Andrew Silver | ) www.reuters.com time to read: +1 min

SHANGHAI, Nov 27 (Reuters) - The spike in respiratory illnesses that China is currently going through is not as high as before the COVID-19 pandemic, a World Health Organisation official said, reiterating that no new or unusual pathogens had been found in the recent cases. And the waves that they’re seeing now, the peak is not as high as what they saw in 2018-2019," Van Kerkhove told health news outlet STAT in an interview on Friday. China's National Health Commission spokesperson Mi Feng said on Sunday the surge in acute respiratory illnesses was linked to the simultaneous circulation of several kinds of pathogens, most prominently influenza. The WHO said on Friday no new or unusual pathogens had been found in the recent illnesses. Reporting by Andrew Silver; Editing by Miyoung Kim and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.

Persons: Maria Van Kerkhove, Van Kerkhove, Mi Feng, Andrew Silver, Miyoung Kim Organizations: Health, World Health Organization, China, Program, WHO, Thomson Locations: SHANGHAI, China, Wuhan

SHANGHAI, Nov 24 (Reuters) - China called for vigilance on Friday as a surge of respiratory illness hit schools and hospitals and the World Health Organization, which has asked the government for disease data, said no unusual or novel pathogens had been detected. The State Council said influenza would peak this winter and spring and mycoplasma pneumoniae infection would continue to be high in some areas in future. "At this stage, there is nothing to suggest that it may be a new variant of COVID," he said. "I hope that people will not be biased because of the pandemic ... but look at this from a scientific perspective." "It's not that bad, there are more children falling sick now but it's mainly an issue of protection," she said.

Persons: Bruce Thompson, Emily Wu, Feng Zixun, Andrew Silver, Nicoco Chan, Brenda Goh, Robert Birsel Organizations: World Health Organization, State Council, State, WHO, Program, Melbourne School of Health Sciences, University of Melbourne, Beijing, Thomson Locations: SHANGHAI, China, Beijing, Liaoning, Wuhan, Shanghai

☆ China Grapples With Respiratory Illness Spike; WHO Says No Unusual Pathogen Found
▼ + stars: | 2023-11-24 | by ( Nov. | At A.M. | ) www.usnews.com time to read: +3 min

By Andrew Silver and Nicoco ChanSHANGHAI (Reuters) - China called for vigilance on Friday as a surge of respiratory illness hit schools and hospitals and the World Health Organization, which has asked the government for disease data, said no unusual or novel pathogens had been detected. "At this stage, there is nothing to suggest that it may be a new variant of COVID," he said. "I hope that people will not be biased because of the pandemic ... but look at this from a scientific perspective." "It's not that bad, there are more children falling sick now but it's mainly an issue of protection," she said. (Reporting by Andrew Silver and Nicoco Chan in Shanghai and the Beijing Newsroom; writing by Brenda Goh; editing by Robert Birsel)

Persons: Andrew Silver, Nicoco Chan, Bruce Thompson, Emily Wu, Feng Zixun, Brenda Goh, Robert Birsel Organizations: World Health Organization, State Council, State, WHO, Program, Melbourne School of Health Sciences, University of Melbourne, Beijing Locations: Nicoco Chan SHANGHAI, China, Beijing, Liaoning, Wuhan, Shanghai

☆ China says no unusual pathogens found after WHO queries respiratory outbreaks
▼ + stars: | 2023-11-23 | by ( ) www.reuters.com time to read: +5 min

The WHO had asked China for more information on Wednesday after groups including the Program for Monitoring Emerging Diseases (ProMED) reported clusters of undiagnosed pneumonia in children in north China. No unusual pathogens have been detected in the capital of Beijing and the northeastern province of Liaoning. The U.N. health agency had also asked China for further information about trends in the circulation of known pathogens and the burden on healthcare systems. WHO China said it was "routine" to request information on increases in respiratory illnesses and reported clusters of pneumonia in children from member states, such as China. The WHO said that while it was seeking additional information, it recommended that people in China follow measures to reduce the risk of respiratory illness.

Persons: Dado Ruvic, pneumoniae, Ben Cowling, Deena Beasley, Andrew Silver, Jennifer Rigby, Emma Farge, Urvi, Robert Birsel, Miyoung Kim, Josie Kao Organizations: REUTERS, World Health Organization, WHO, International, National Health Commission, FTV News, Hong Kong University, Health Commission, Xinhua, Influenza, Thomson Locations: China, Beijing, Liaoning, Wuhan, WHO China, Taiwan, Los Angeles, Shanghai, London, Geneva, Bengaluru

China detained the executive, named in several media reports as Hiroshi Nishiyama, on suspicion of espionage in March, and he was formally arrested last month. Japan's then foreign minister protested the executive's detention with his Chinese counterpart on a visit to Beijing in April. China's foreign ministry did not immediately respond to a request for comment. Half the respondents in a recent survey of Japanese companies doing business in China said they would cut investments this year. It's a very difficult point in time to be navigating that as a decision maker, in business or politics," he said.

Persons: Fumio Kishida, Xi Jinping, Rahm Emanuel, Hiroshi Nishiyama, Japan's, Xi, Masashi Mizobuchi, Nishiyama, Takeshi Niinami, Niinami, Stefan Angrick, Yukiko Toyoda, Kiyoshi Takenaka, John Geddie, Sakura Murakami, Francis Tang, Laurie Chen, Antoni Slodkowski, Andrew Silver, Lincoln Organizations: Economic Cooperation, Kyodo, drugmaker Astellas Pharma, APEC, Reuters, Japanese Chamber of Commerce, Japan Association of Corporate, Suntory, Moody's Analytics, Thomson Locations: Asia, Bangkok, Thailand, TOKYO, BEIJING, China, San Francisco, Tokyo, U.S, Japan, Beijing, officialdom, Shanghai

☆ China health sector sees better sentiment from anti-graft drive - execs
▼ + stars: | 2023-11-09 | by ( Andrew Silver | ) www.reuters.com time to read: +2 min

SHANGHAI, Nov 9 (Reuters) - Business activities in China's healthcare sector are returning from a sudden near freeze that began in July when Beijing kicked off a year-long anti-corruption campaign, two foreign industry executives said. The campaign targets the bribing of doctors in drug and medical equipment sales and marks a sharp escalation of an anti-corruption drive in the sector that started years ago. The latest campaign has sent a chill through the sector, pummeling healthcare stocks and prompting some firms to cancel IPOs. The anti-graft drive initially caused huge business disruptions and many multinational pharmaceutical firms lost engagement with hospitals, executives said. China is one of the biggest healthcare markets for global healthcare companies but their business sentiment has turned fragile this year due to factors including the anti-graft drive.

Persons: We’ve, Larry Merizalde, Merizalde, Andrew Silver, Miyoung Kim, Robert Birsel Organizations: Beijing, Reuters, South, AstraZeneca, National Health Commission, Thomson Locations: SHANGHAI, China, Shanghai

In a report published Monday, the London-based Environmental Investigation Agency urged global investors in the three firms - Beijing Tong Ren Tang group (600085.SS), Tianjin Pharmaceutical group (600329.SS) and Jilin Aodong Pharmaceutical Group (000623.SZ) - to divest their stakes. The group said it focused on the pharmaceutical companies because they are publicly listed, and display products that include leopard or pangolin parts on their websites. Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to several emails and calls from Reuters asking for comment. Jilin Aodong Pharmaceutical Group could not be reached for comment. The environmental group said Deutsche Bank, HSBC Holdings, Citigroup and BlackRock did not respond to its queries.

Persons: pangolin, Seun, Beijing Tong Ren Tang, Avinash Basker, Wells, China's, Andrew Silver, Selena Li, Miyoung Kim Organizations: REUTERS, Rights, UBS, HSBC, Environmental Investigation Agency, Tianjin Pharmaceutical, Jilin Aodong Pharmaceutical, TCM, Deutsche Bank, HSBC Holdings, Citigroup, BlackRock, & Co, HSBC Global Asset Management Canada, Royal Bank of Canada, Citigroup ， Deutsche Bank, Reuters, Medical Products Administration, Protection, Thomson Locations: Lagos, Nigeria, Rights SHANGHAI, HONG KONG, London, Beijing, Tianjin, Jilin, Shanghai, Hong Kong

☆ Three Listed Chinese Firms Used Endangered Animal Parts as Ingredients Report
▼ + stars: | 2023-10-22 | by ( Oct. | At P.M. | ) www.usnews.com time to read: +3 min

In a report published Monday, the London-based Environmental Investigation Agency urged global investors in the three firms - Beijing Tong Ren Tang group, Tianjin Pharmaceutical group and Jilin Aodong Pharmaceutical Group - to divest their stakes. The group said it focused on the pharmaceutical companies because they are publicly listed, and display products that include leopard or pangolin parts on their websites. Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to several emails and calls from Reuters asking for comment. Jilin Aodong Pharmaceutical Group could not be reached for comment. The environmental group said Deutsche Bank, HSBC Holdings, Citigroup and BlackRock did not respond to its queries.

Persons: Andrew Silver, Selena Li SHANGHAI, Beijing Tong Ren Tang, Avinash Basker, Wells, China's, Selena Li, Miyoung Kim, Miral Organizations: Reuters, UBS, HSBC, Environmental Investigation Agency, Tianjin Pharmaceutical, Jilin Aodong Pharmaceutical, TCM, Deutsche Bank, HSBC Holdings, Citigroup, Co, HSBC Global Asset Management Canada, Royal Bank of Canada, BlackRock, Citigroup ， Deutsche Bank, Medical Products Administration, Protection Locations: HONG KONG, London, Beijing, Tianjin, Jilin, BlackRock, Shanghai, Hong Kong

REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsLONDON/SHANGHAI Oct 9 (Reuters) - China's largest vaccines company Zhifei (300122.SZ) will pay British drugmaker GSK (GSK.L) 2.5 billion pounds ($3.05 billion pound) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 pharmaceuticals market. The deal with Zhifei is part of its efforts to reach more 4 billion pounds ($4.88 billion) in sales by 2026, GSK said. Zhifei will purchase volumes of Shingrix with a value to GSK worth 2.5 billion pounds over an initial three-year period, GSK said. Zhifei shares were up as much as 20% to 58.40 yuan ($8.00) following the filing, their highest point since March 27. Shingrix is currently GSK's biggest product and strongest growth driver, taking in 1.71 billion pounds in first-half sales, up 20% from a year prior.

Persons: Dado Ruvic, Zhifei, Shingrix, Maggie Fick, Andrew Silver, Eva Mathews, Savio D'Souza, Louise Heavens Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, Zhifei, Barclays, Reuters, Thomson Locations: SHANGHAI, China, United States, London, Shanghai, Bengaluru

☆ Illegal Mopeds and Fake Names: Migrants Scrape By in Underground Economy
▼ + stars: | 2023-09-15 | by ( Andrew Silverstein | ) www.nytimes.com time to read: +1 min

At the same time, a new cottage industry of black-market moped brokers has emerged to serve — and sometimes prey upon — the newest migrants, who arrive with little money, no bank account and no tax ID or Social Security number. He makes deliveries all over Manhattan and into Brooklyn, sometimes as many as 30 a day. For each order, Uber Eats pays him a fee determined by an algorithm, about $4 on average; customers can add a tip through the app. “Jessica” receives all his earnings as a direct deposit into her bank account, and then hands over his payments and tips in cash, minus the fee. Mr. Milano had to borrow money from another migrant to cover his moped rental.

Persons: Mr . Milano, Jessica, ”, Uber, Jessica ”, Milano Organizations: Mr Locations: Venezuela, United States, Venezuelan, Manhattan, Brooklyn

☆ Schonfeld is rolling out a team focused on credit in another sign of Wall Street's rising interest in debt investing
▼ + stars: | 2022-10-31 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +5 min

Everybody wants to be a lender these daysStop me if you've heard this before, but a Wall Street firm wants to invest in debt. Schonfeld Strategic Advisors, the $14 billion family-office-turned-hedge fund is building out a new group focused on credit within its macro trading business, Insider reports. A general rule on Wall Street is that firms like to build businesses around complex things. A simple process means it is easily repeatable by someone else, which means more competition, which means smaller margins, which means less profit. The SEC issued $2.2 billion in fines on public companies, including 13 fines larger than $100 million, during its 2022 fiscal year, The Wall Street Journal reports.

☆ $14 billion Schonfeld is launching a new credit unit as the hedge fund continues its growth tear
▼ + stars: | 2022-10-28 | by ( Alyson Velati | ) www.businessinsider.com time to read: +3 min

$14 billion Schonfeld Strategic Advisors has rolled out a credit unit within its new macro trading business that launched earlier this year. Silverman and Aubrey joined in July and August, respectively, following Anchorage shutting its $7.4 billion hedge fund last December. The expanding credit business is part of Schonfeld's recent growth tear. In January, the firm is rolling out long/short credit strategies across the credit quality spectrum in the US and plans to add APAC and EMEA strategies over time. The HFRI Asset Weighted Index gained 1.1% for September, increasing the year-to-date return to 3.8%, according to Hedge Fund Research data.

Search resuls for: "Andrew Silver"

15 mentions found